ES2637852T3 - Lactoferrina para usar en el tratamiento de parto prematuro y aborto espontáneo - Google Patents
Lactoferrina para usar en el tratamiento de parto prematuro y aborto espontáneo Download PDFInfo
- Publication number
- ES2637852T3 ES2637852T3 ES13826955.0T ES13826955T ES2637852T3 ES 2637852 T3 ES2637852 T3 ES 2637852T3 ES 13826955 T ES13826955 T ES 13826955T ES 2637852 T3 ES2637852 T3 ES 2637852T3
- Authority
- ES
- Spain
- Prior art keywords
- lactoferrin
- treatment
- miscarriage
- preterm birth
- intravagian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000010445 Lactoferrin Human genes 0.000 title abstract 3
- 108010063045 Lactoferrin Proteins 0.000 title abstract 3
- 229940078795 lactoferrin Drugs 0.000 title abstract 3
- 235000021242 lactoferrin Nutrition 0.000 title abstract 3
- 206010000234 Abortion spontaneous Diseases 0.000 title abstract 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title abstract 2
- 208000000995 spontaneous abortion Diseases 0.000 title abstract 2
- 208000005107 Premature Birth Diseases 0.000 title 1
- 208000015994 miscarriage Diseases 0.000 title 1
- 206010036595 Premature delivery Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Lactoferrina para usar en la prevención y tratamiento de parto prematuro y aborto espontáneo, que consiste en administrar una vez o dos veces al día mediante ruta intravagianal tópica a un sujeto que lo necesita una forma de dosificación unitaria, que consiste en: - lactoferrina en cantidades de 250 a 800 mg y - al menos un excipiente adecuado para toma intravaginal.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20122152 | 2012-12-17 | ||
| IT002152A ITMI20122152A1 (it) | 2012-12-17 | 2012-12-17 | Composizione per uso topico. |
| PCT/IB2013/060994 WO2014097123A1 (en) | 2012-12-17 | 2013-12-16 | Composition for topical use comprising lactoferrin. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2637852T3 true ES2637852T3 (es) | 2017-10-17 |
Family
ID=47683866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13826955.0T Active ES2637852T3 (es) | 2012-12-17 | 2013-12-16 | Lactoferrina para usar en el tratamiento de parto prematuro y aborto espontáneo |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150320839A1 (es) |
| EP (1) | EP2931303B1 (es) |
| ES (1) | ES2637852T3 (es) |
| IT (1) | ITMI20122152A1 (es) |
| WO (1) | WO2014097123A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2992894A1 (en) * | 2014-09-05 | 2016-03-09 | Progine Farmaceutici Srl | Vaginal formulations for preventing and treating vaginal and cervico-vaginal infections |
| CN110619802A (zh) * | 2019-11-01 | 2019-12-27 | 上海市第一妇婴保健院 | 一种宫颈环扎术模拟教学用医学模型 |
| IT202000022420A1 (it) * | 2020-09-23 | 2022-03-23 | Microbo Srl | Formulazioni per somministrazioni topiche mucosali e/o orali sistemiche contenenti una miscela a base di lattoferrina, più efficace nella captazione del ferro, per la prevenzione e trattamento di varie patologie |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3872797A (en) | 1996-08-12 | 1998-03-06 | A+ Science Invest Ab | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
| CA2466542A1 (en) | 2001-12-05 | 2003-06-12 | Dsm Ip Assets B.V. | Methods and compositions for use in pet breeding |
| WO2004060392A1 (en) | 2002-12-20 | 2004-07-22 | Ventria Bioscience | Lactoferrin protein with iron for treating iron deficiency and anemia |
| SE528337C2 (sv) * | 2004-06-23 | 2006-10-24 | Nestor Medical Ab | Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet |
| WO2006098625A1 (en) * | 2005-03-15 | 2006-09-21 | Campina Nederland Holding B.V. | Dermatologic use of milk proteins |
| IT1392620B1 (it) * | 2008-10-10 | 2012-03-16 | Progine Farmaceutici Srl | Preparato a base di lattoferrina per prevenire aborti spontanei, rottura prematura delle membrane e parti pretermine |
| EP2251030A1 (en) | 2009-05-12 | 2010-11-17 | Nestec S.A. | Lactoferrin and brain health and development in infants |
| WO2011150393A2 (en) * | 2010-05-28 | 2011-12-01 | Bmg Hematology Llc | Methods for improving maternal and fetal health |
| IT1406153B1 (it) * | 2010-12-23 | 2014-02-14 | Microbo Srl | Metodi di prevenzione e terapia per parti e nascite pretermine. |
| CA2823018A1 (en) | 2010-12-29 | 2012-07-05 | Mjn U.S. Holdings Llc | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions |
-
2012
- 2012-12-17 IT IT002152A patent/ITMI20122152A1/it unknown
-
2013
- 2013-12-16 ES ES13826955.0T patent/ES2637852T3/es active Active
- 2013-12-16 US US14/652,128 patent/US20150320839A1/en not_active Abandoned
- 2013-12-16 WO PCT/IB2013/060994 patent/WO2014097123A1/en not_active Ceased
- 2013-12-16 EP EP13826955.0A patent/EP2931303B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014097123A1 (en) | 2014-06-26 |
| US20150320839A1 (en) | 2015-11-12 |
| ITMI20122152A1 (it) | 2014-06-18 |
| EP2931303B1 (en) | 2017-07-19 |
| EP2931303A1 (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125144T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| MX367241B (es) | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BR112015021002B8 (pt) | Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| AR091089A1 (es) | Metodos de tratamiento que utilizan un compuesto de biguanida en una formulacion de liberacion demorada | |
| AR060880A1 (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| MX2015009142A (es) | Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. | |
| AR086395A1 (es) | Envase para el tratamiento de patologias | |
| ES2629309T3 (es) | Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora | |
| ES2637852T3 (es) | Lactoferrina para usar en el tratamiento de parto prematuro y aborto espontáneo | |
| BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
| UY34178A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos. | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| BR112012026285A2 (pt) | combinação de compostos orgânicos |